{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-309122","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.042177+00:00","generated_at":"2026-06-21T01:50:51.994963+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Eliem Therapeutics sets 2023 base salaries and bonuses for named executives","bullets":["CEO Azelby: $438,750 2022 bonus; 2023 base $702,000, 65% target bonus (company goals only).","COO/CFO Lavelle: $209,588 2022 bonus; 2023 base $484,380, 45% target bonus.","CSO Morisset: £145,467 2022 bonus; 2023 base £336,190, 45% target bonus.","2023 company performance goals to be set later by Board; individual goals subjective."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-309122","json":"https://secwatch.observer/filing/0001193125-22-309122.json","markdown":"https://secwatch.observer/filing/0001193125-22-309122.md","text":"https://secwatch.observer/filing/0001193125-22-309122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312522309122/0001193125-22-309122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312522309122/d399841d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T01:50:51.994963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}